| Head and neck squamous cell carcinoma DE Johnson, B Burtness, CR Leemans, VWY Lui, JE Bauman, JR Grandis Nature reviews Disease primers 6 (1), 92, 2020 | 2560 | 2020 |
| Phase II study of daily sunitinib in FDG-PET–positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging … LL Carr, DA Mankoff, BH Goulart, KD Eaton, PT Capell, EM Kell, ... Clinical Cancer Research 16 (21), 5260-5268, 2010 | 501 | 2010 |
| E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of … S Marur, S Li, AJ Cmelak, ML Gillison, WJ Zhao, RL Ferris, WH Westra, ... Journal of Clinical Oncology 35 (5), 490-497, 2017 | 467 | 2017 |
| Drug repurposing from an academic perspective TI Oprea, JE Bauman, CG Bologa, T Buranda, A Chigaev, BS Edwards, ... Drug Discovery Today: Therapeutic Strategies 8 (3-4), 61-69, 2011 | 365 | 2011 |
| Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial RG Martins, U Parvathaneni, JE Bauman, AK Sharma, LE Raez, ... Journal of clinical oncology 31 (11), 1415-1421, 2013 | 243 | 2013 |
| Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma ML Hedberg, G Goh, SI Chiosea, JE Bauman, ML Freilino, Y Zeng, ... The Journal of clinical investigation 126 (1), 169-180, 2016 | 220 | 2016 |
| The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations JL Geiger, JR Grandis, JE Bauman Oral oncology 56, 84-92, 2016 | 183 | 2016 |
| A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of … JA Vargo, RL Ferris, J Ohr, DA Clump, KS Davis, U Duvvuri, S Kim, ... International Journal of Radiation Oncology* Biology* Physics 91 (3), 480-488, 2015 | 160 | 2015 |
| Promising systemic immunotherapies in head and neck squamous cell carcinoma N Gildener-Leapman, RL Ferris, JE Bauman Oral oncology 49 (12), 1089-1096, 2013 | 138 | 2013 |
| Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT MN Theodoraki, S Yerneni, WE Gooding, J Ohr, DA Clump, JE Bauman, ... Oncoimmunology 8 (7), e1593805, 2019 | 131 | 2019 |
| Treatment of recurrent squamous cell carcinoma of the skin with cetuximab JE Bauman, KD Eaton, RG Martins Archives of Dermatology 143 (7), 889-892, 2007 | 125 | 2007 |
| Molecular characterization of apocrine salivary duct carcinoma SI Chiosea, L Williams, CC Griffith, LDR Thompson, I Weinreb, ... The American journal of surgical pathology 39 (6), 744-752, 2015 | 118 | 2015 |
| Salvage lung resection after definitive radiation (> 59 Gy) for non-small cell lung cancer: surgical and oncologic outcomes JE Bauman, MS Mulligan, RG Martins, BF Kurland, KD Eaton, DE Wood The Annals of thoracic surgery 86 (5), 1632-1639, 2008 | 111 | 2008 |
| A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma JE Bauman, H Arias-Pulido, SJ Lee, MH Fekrazad, H Ozawa, E Fertig, ... Oral oncology 49 (5), 461-467, 2013 | 106 | 2013 |
| Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients HB Jie, RM Srivastava, A Argiris, JE Bauman, LP Kane, RL Ferris Cancer immunology research 5 (5), 408-416, 2017 | 103 | 2017 |
| Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck: the active8 randomized … RL Ferris, NF Saba, BJ Gitlitz, R Haddad, A Sukari, P Neupane, JC Morris, ... JAMA oncology 4 (11), 1583-1588, 2018 | 102 | 2018 |
| Prevention of carcinogen-induced oral cancer by sulforaphane JE Bauman, Y Zang, M Sen, C Li, L Wang, PA Egner, JW Fahey, ... Cancer prevention research 9 (7), 547-557, 2016 | 96 | 2016 |
| A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and … A Jimeno, JE Bauman, C Weissman, D Adkins, I Schnadig, P Beauregard, ... Oral oncology 51 (4), 383-388, 2015 | 96 | 2015 |
| A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma TJ Galloway, LJ Wirth, AD Colevas, J Gilbert, JE Bauman, NF Saba, ... Clinical Cancer Research 21 (7), 1566-1573, 2015 | 95 | 2015 |
| Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition B Burtness, JE Bauman, T Galloway The lancet oncology 14 (8), e302-e309, 2013 | 92 | 2013 |
